Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : J&J Unit Gets FDA Priority Review of Invokana in Chronic Kidney Disease

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/22/2019 | 09:37am EDT

By Colin Kellaher

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Wednesday said the U.S. Food and Drug Administration granted priority review to its supplemental new-drug application for the diabetes drug Invokana in patients with chronic kidney disease.

The drug maker is seeking approval for Invokana to reduce the risk of end-stage kidney disease, the doubling of serum creatinine, and renal or cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period to six months from the standard 10 months.

Janssen said Invokana, if approved for the new indication, would be the first and only diabetes medicine to treat chronic kidney disease in patients with type 2 diabetes.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
05:46aJOHNSON & JOHNSON : FDA - Baby powder manufacturer voluntarily recalls products ..
AQ
05:45aJOHNSON & JOHNSON : Janssen Receives Positive CHMP Opinion for Spravato Nasal Sp..
AQ
01:12aJOHNSON & JOHNSON : Wall St drags on Boeing and Chinese data
AQ
12:35aJOHNSON & JOHNSON : 1st federal opioid crisis trial to focus on distribution
AQ
10/19JOHNSON & JOHNSON : J&J Recalls Baby Powder on Asbestos Concern -- 3rd Update
DJ
10/19J&J Recalls Baby Powder For Asbestos -- WSJ
DJ
10/18MARKET SNAPSHOT: Dow Ends Lower Pressured By Boeing, Johnson & Johnson, Despi..
DJ
10/18JOHNSON & JOHNSON : J&J Recalls Baby Powder on Asbestos Concern -- 2nd Update
DJ
10/18JPMORGAN CHASE, FACEBOOK, COCA-COLA : Stocks That Defined the Week
DJ
10/18CARDINAL HEALTH : Opioid negotiations fail to produce deal just before trial
AQ
More news
Financials (USD)
Sales 2019 82 226 M
EBIT 2019 25 622 M
Net income 2019 19 665 M
Debt 2019 7 881 M
Yield 2019 2,94%
P/E ratio 2019 17,7x
P/E ratio 2020 16,6x
EV / Sales2019 4,19x
EV / Sales2020 3,93x
Capitalization 337 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 149,16  $
Last Close Price 127,70  $
Spread / Highest target 35,5%
Spread / Average Target 16,8%
Spread / Lowest Target 1,02%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.05%337 021
ROCHE HOLDING AG18.88%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.10%198 751
NOVO NORDISK AS17.69%123 560